 Home > Active Ingredient News >

Blood System

Blood: In multiple myeloma, monoclonal immunoglobulin promotes bone loss

 Time of Update: 2020-07-12

polyglutamic acid serum neural precursor cells stem cells used ph 1 acid model behavior

Most patients with multiple myeloma develop severe bone-soluble diseases Myeloma cells secrete immune globulin, the presence of monoclonal immunoglobulin in the serum of patients is important dia
Brukinsa, a BTK inhibitor in Baiji Shenzhou, is under review in Europe for the treatment of Fahrenheit polycyloproteinemia

 Time of Update: 2020-07-12

fda approved epoxy 1 cell phone key chinese 1 4 dibromobenzene cell gene therapy

Brukinsa (zanubrutinib, Zebtinib), a BTK small molecule inhibitor developed by Baiji Shenzhou, has been censored by European regulators to treat patients with Fahrenheit polycyteproteinemia (WM)
59-year-old patient without cancer markers for more than 3 years after receiving CAR-T cell immunotherapy

 Time of Update: 2020-06-25

he detergent pods cell malignancies cell suspension culture fda medical device labeling seds medical

Even after three years, Andrew Parker and his oncologist, Michael Bishop, m.D., at the University of Chicago Medical Center, are in awe of the amazing turn of CAR-T cell immunotherapy 2016, Parker
Gene therapy LentiGlobin Treatment of Sickle Cell Disease: Phase I / Phase II Clinical Positive Results

 Time of Update: 2020-06-25

huntington's disease treatment year bluebird bio sickle cell malaria cell culture company

The latest data from Bluebird Bio's ongoing phase I/II study of gene therapy LentiGlobin for the treatment of sickle cell disease (SCD) shows that severe vascular aocstatory crisis (VOC) and acute
Baiji Shenzhou announced that combination chemotherapy was used in non-squamous non-small cell lung cancer patients, the stage 3 trial reached the main end point of progression-free survival

 Time of Update: 2020-06-25

brain cancer survival blood blood free uses monoclonal antibodies small fuel cell new drug approvals

Baiji Shenzhou announced that its anti-PD-1 monoanti-relizumab combined permeitus and platinum chemotherapy, a phase 3 trial for first-line treatment of non-squamous non-small cell lung cancer (NSCL
Concerned about the rare disease "Red Blood Cell-producing Prosofe and X-Chain Dystrophy": Launched Global Phase III Clinical Trials of MT-7117

 Time of Update: 2020-06-25

hemoglobin blood test primary cell liver glucose production blood cell size red blood cells oxygen

Mitsubishi Tianbian Pharmaceutical Co., Ltd announced today that it has begun a global Phase III clinical trial of MT-7117, a selective black skin quality 1 receptor (MC1R) agonisant, aimed at treat
FDA Awards FT-4202 Orphan Drug for Sickle Cell Disease

 Time of Update: 2020-06-25

aristada fda approval which organ produces cholesterol vascular proliferation used cell disease

FORMA, a clinically phased biopharmaceutical company focused on rare haematology diseases and cancers, recently announced that the FDA has awarded its FT-4202 orphan drug designation, which is curre
Collection: Collection of Blood Research Highlights, April 16, 2020

 Time of Update: 2020-06-25

high viscosity oil hormone type 1 copper based blood 2 3 butanediol main source protein

The volume of high-start total metabolic tumors helps identify ultra-high-risk DLBCL populations https://doi.org/10.1182/blood.2019003526 https://doi.org/10.1182/blood.2019003526 early identif
PKR activator mitapivat treatment of thalassemia: continued improvement in patient hemoglobin levels

 Time of Update: 2020-06-25

bone diseases symptoms 100 mg trazodone 1 6 symbol low dose ibuprofen namenda 10 mg

Agios Pharmaceuticals recently reported on Phase II studies showing that its experimental oral drug mitapivat (PKR activator) significantly improved hemoglobin (Hb) levels and the associated markers
NMPA approves anti-PD-1 monoanti-relylibeads in Baiji Shenzhou for the treatment of locallate or metastatic urethral skin cancer

 Time of Update: 2020-06-25

anti ro antibody review 2 pd 1 pd l1 pathway platinum drugs pd 1 immunotherapy

Baiji Shenzhou announced that its anti-PD-1 antibody tislelizumab (tislelizumab) has been approved by the State Drug Administration of China (NMPA) for pD-L1 high expression, during or after platinu
Blood: The best drug for isosome platelet hyperplasia, aspirin optimizes antiplatelet therapy

 Time of Update: 2020-06-25

estazolam 2 mg 1 4 liter ritalin 40 mg 1 3 bisphosphoglycerate what 2 4

Ispeciallyanocal hyperplasia (ET) is characterized by abnormal macrocytocell production and an increased risk of blood clots Recommended antithrombotic treatment options: small dose aspirin, once da
A selection of Lancet research highlights on April 18, 2020

 Time of Update: 2020-06-25

mg 3 1000 mg aspirin dolac 10 mg phenylephrine 20 mg fentanyl 25 mg

1 Gixithabin-Platinum Chemotherapy for the late-stage epithelial skin cancer DOI: https://doi.org/10.1016/S0146/S0146-6736 (20)30415-3 is rare and pre-conditioned than bladder ontheuliopath
Blood: Vascular autonomic nerve function abnormalities in sickle cell disease (SCD)

 Time of Update: 2020-06-25

helium recovery system sickle cell curable blood vessel wall cold hot cpt2 disease symptoms

Subjects of sickle cell disease (SCD) exhibited subjective hypersensitivity to cold and hot sensations in the experimental environment, such as cold exposure and other known causes that cause the p
Lancet: Acalabrutinib's first-line treatment of chronic lymphocytic leukemia is effective

 Time of Update: 2020-06-25

15 6 simplified 3 pi 4 ps 12 3 immunotherapy rho kinase inhibitor

Acalabrutinib is an alternative Bruton tyrosine kinase inhibitor that has the activity to treat chronic lymphocytic leukemia The researchers looked at the efficacy of Acalabrutinib in the treatment
AACR 2020: Ibtinib and Litoxi monotherapy follicle lymphoma Phase III Research Launch (PERSPECTIVE Study)

 Time of Update: 2020-06-24

org chem group 1 2 4 triazole 2 glasses 69 brake system parts study spiders

research background For elderly or patients with fissyllosic lymphoma (FL), the first-line chemo-free (no chemotherapy) treatment options are very limited At present, rituximatomaishasis has been
Cell Metab: Lactic acid regulates muscle ischemia

 Time of Update: 2020-06-24

clogged blood vessels regulator blood lactic acid 10 lactic acid mask

Endothelial cells (EC) produce signals that help organs regenerate, but there have been reports of metabolic communication within blood vessels recently, researchers found that EC-specific glycoen
Bcl-2 inhibitor APG-2575 for use in chronic lymphocytic leukemia or small lymphocytic lymphoma in Phase Ib/II clinical, approved by NMPA

 Time of Update: 2020-06-24

anti antibodies small cell lymphoma microscopic cancer cells mouse monoclonal antibodies anti musk antibodies

Ascentage Pharma announced that it has received approval from the State Drug Administration of China (NMPA) for its Ib/II phase of its new Bcl-2 selective inhibitor APG-2575 to treat recurrent/refra
Blood: Effects of arginine therapy on mitochondrial function during vascular closed pain in sickle cell disease in children

 Time of Update: 2020-06-24

1 2 crown et 300 manual reciprocal 1 2 zonisamide 100 mg dig 6 3

The mitochondrial function of sickle cell disease (SCD) changes, in part because of the low bioavailability of nitric oxide (NO) Arginine is the substrate that produces NO and becomes severely defic
Virol J: Non-transplantative acute leukemia patients receiving chemotherapy combined with human herpes virus

 Time of Update: 2020-06-24

reciprocal 1 2 ebv pcr dig 6 3 5 6 models 7 3 chemo

The human herpes virus (HHVs) still has an incubation period after primary infection and can be reactivated after immunosuppression and chemotherapy Little is known about its incidence, potential re
Blood: Three aspirin treatment options in optimizing isoplate hyperpluse patients with antiplatelet treatment comparison

 Time of Update: 2020-06-24

arginine daily dose cotinine blood sheep blood agar 1 2cv 2 test tube blood

Ispeciallyanocal hyperplasia (ET) is characterized by abnormal macrocytocell production and an increased risk of blood clots Daily small-dose (od) aspirin is the recommended antithrombotic treatment

Go to Page

Blood System

Blood: In multiple myeloma, monoclonal immunoglobulin promotes bone loss

Brukinsa, a BTK inhibitor in Baiji Shenzhou, is under review in Europe for the treatment of Fahrenheit polycyloproteinemia

59-year-old patient without cancer markers for more than 3 years after receiving CAR-T cell immunotherapy

Gene therapy LentiGlobin Treatment of Sickle Cell Disease: Phase I / Phase II Clinical Positive Results

Baiji Shenzhou announced that combination chemotherapy was used in non-squamous non-small cell lung cancer patients, the stage 3 trial reached the main end point of progression-free survival

Concerned about the rare disease "Red Blood Cell-producing Prosofe and X-Chain Dystrophy": Launched Global Phase III Clinical Trials of MT-7117

FDA Awards FT-4202 Orphan Drug for Sickle Cell Disease

Collection: Collection of Blood Research Highlights, April 16, 2020

PKR activator mitapivat treatment of thalassemia: continued improvement in patient hemoglobin levels

NMPA approves anti-PD-1 monoanti-relylibeads in Baiji Shenzhou for the treatment of locallate or metastatic urethral skin cancer

Blood: The best drug for isosome platelet hyperplasia, aspirin optimizes antiplatelet therapy

A selection of Lancet research highlights on April 18, 2020

Blood: Vascular autonomic nerve function abnormalities in sickle cell disease (SCD)

Lancet: Acalabrutinib's first-line treatment of chronic lymphocytic leukemia is effective

AACR 2020: Ibtinib and Litoxi monotherapy follicle lymphoma Phase III Research Launch (PERSPECTIVE Study)

Cell Metab: Lactic acid regulates muscle ischemia

Bcl-2 inhibitor APG-2575 for use in chronic lymphocytic leukemia or small lymphocytic lymphoma in Phase Ib/II clinical, approved by NMPA

Blood: Effects of arginine therapy on mitochondrial function during vascular closed pain in sickle cell disease in children

Virol J: Non-transplantative acute leukemia patients receiving chemotherapy combined with human herpes virus

Blood: Three aspirin treatment options in optimizing isoplate hyperpluse patients with antiplatelet treatment comparison